IDDI
ADDING VALUE TO CLINICAL DATA

Name · **IDDI**

Address/P.O. Box · **30, Avenue Provinciale**
Postal Code/City · **1340 Louvain la Neuve**
Country · **Belgium**
Contact Person · **Catherine Indekeu**
Telephone · **+32-10614444**
Fax · **+32-10618888**
Email Address · **Catherine.indekeu@iddi.com**
Internet Website · **www.IDDI.com**
Number of Employees · **62 FTE**
Founded (year) · **1991**
Areas of Activity · **eClinical and Biostatistical Services for Clinical Trials**

Annual Turnover · **8 million euros**

Relevant R&D Budget · **5% of annual costs**

INTERNATIONAL DRUG DEVELOPMENT INSTITUTE (IDDI)

Expert provider in eClinical and Biostatistical Services

Established in 1991 and based in Louvain-la-Neuve since 2006, IDDI (International Drug Development Institute) with a staff of around 70 people combines expert methodology and innovative technology to optimize the design and conduct of clinical trials from phase I to IV.

The dynamic development of the group (30% increase in turnover (90% exports) between 2010 and 2012) is based on its niche positioning in the fields of biostatistics, data management and central randomization (automation of controlled allocation of treatments in randomized clinical trials). IDDI also provides biostatistical support for the design of trial protocols and acts as an expert for interactions with regulatory agencies (EMA, FDA).

Methodological support is the core of IDDI's expertise. Comparable to high-level consultancy, it integrates biostatistical know-how in many therapeutic areas (with emphasis on oncology, ophthalmology and cardiology) and enables the optimal design of clinical trial protocols in order to obtain results more swiftly.

In parallel, IDDI provides integrated e-Clinical Solutions: made-to-measure secure web systems:
Centralized treatment allocation and Drug supply management (ID-net™), Electronic Data Capture, Coding of medical terms (ID-code™) according to the MedDRA® and WHO-Drug Dictionary.

Over 22 years of activity, IDDI has conducted around 500 clinical trials and contributed to 15 approvals to market new drugs in Europe and the USA.
Over the last 5 years IDDI has worked with 160 clients worldwide (the majority are biotechnology companies, and out of the top ten pharmaceutical groups and general prestigious academic groups). Repeat business at IDDI is high (over 75% of clients rely on IDDI to manage additional studies in their pipeline).

UNRIVALED EXPERIENCE FOR 22 YEARS

BEST IN CLASS BIOSTATISTICS

INTEGRATED EDC/IWRS

WE KEEP OUR STAFF HAPPY TO KEEP YOU HAPPY

In order to meet growth from US clients (more than half of its revenue), and the strategic commitment to develop the company presence in North America, IDDI has offices in Boston, MA and Houston, TX.
IDDI's culture is scientifically driven, thanks to its Founder Marc Buyse.
In this context, no surprise that IDDI invests in two research projects: The SMART project, developed with the financial support of the Walloon Region, aims to design innovative statistical methods with a view to detect heterogeneity of data across investigational centres and to assess and improve the quality of clinical trial data. After having invested for over a decade in this research project, IDDI launched early 2013 a dedicated subsidiary called CluePoints providing a unique Central Statistical Monitoring approach based on the SMART™ engine.
The second project, BRAVO: Biomarker Retrospective Analysis for Validation Optimization under the Eurotrans-Bio initiative, has already delivered its findings: an innovative statistical methodology to speed up and improve the validation of biomarkers in Alzheimer's disease.

IDDI's success stories reflect the group's dynamism. In the early 2000s, IDDI advised a US biotech planning to enter into Phase II to perform 2 combined Phase II/III trials in order to test for different doses. As a result, one year was saved in the successful submission procedure of this new ophthalmic drug to FDA and EMA. More recently, IDDI advised a French biotech to adopt a Bayesian design and a seamless transition between Phase II and III, using a biomarker to better select patients who benefit from treatment. This innovative approach was approved by FDA. IDDI helped an ophthalmology company to switch from paper CRFs to EDC in five weeks using a hybrid DM system in order to ease and speed up clinical operations. The group also contributed to the validation of prognostic and predictive biomarkers in breast and colon cancer.

These success stories have enabled IDDI to develop strategic collaborations with leading biotechnology companies world-wide. For instance, IDDI supports the central randomization and EDC support for a leading US biotech company in 5 large Phase II and III trials in hepatitis. . . .